Home › Research › How common it is
Antipsychotic prescriptions in people with dementia in primary care: a cohort study investigating adherence of dose and duration to UK clinical guidelines
Holly Christina Smith, Irene Petersen, Joseph Hayes, Kelvin P. Jordan, Magnus Boman, Sube Banerjee, Kate R Walters, Claudia Cooper et al.. The Lancet Psychiatry, 2025-09-17
Topic: Risk, prevention and care in population studies
Plain-language summary
In our dataset search, we identified 108 910 people with a record indicating dementia at any time. In total, 99 091 cases were excluded (ie, individuals with no antipsychotic prescription between the ages of 60 and 85 years between 2000 and 2023, a previous history of antipsychotics, missing deprivation information, or only one eligible prescription). We included 9819 people living with dementia aged 60-85 years who received their first antipsychotic prescription between 2000 and 2023 in the study. 5310 (54·1%) were female and 4509 (45·9%) were male, with a mean age of 77·1 years (SD 5·6 years), and ethnicity data were not available. The first treatment episode lasted a median of 7 months (IQR 6·6-8·7), exceeding NICE guidelines of 1-3 months and 18·1% [95% CI 17·4-18·9]) were initiated on a prescription above the minimum effective dose (ie, low dose). Of the 1781 participants who started on a moderate or high dose, 519 (29·1%) had a moderate or high dose in all quarters of the first year of treatment. 1 year after treatment initiation, 5136 (78·3%) of 6559 eligible individuals remained on medication (48·9% [95% CI 47·7-50·1] on low dose, 14·8% [13·9-15·6] on moderate or high dose of haloperidol, olanzapine, quetiapine or risperidone; and 14·6% [13·8-15·5] on other antipsychotics). Of the 5547 individuals eligible to restart treatment after initial discontinuation, 3106 (56%) restarted with a median treatment duration of 2·6 months (IQR 0·0-9·9). This study highlights how antipsychotic prescribing in dementia is discordant with current NICE guidelines on both duration and dose. More than half of those who discontinued their treatment then restarted treatment. These findings emphasise a persistent gap between clinical guidelines and real-world prescribing, underscoring the need for interventions that prioritise safety and person-centred dementia care. FUNDING: National Institute for Health and Care Research School for Primary Care Research.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 9,819 participants. In UK primary care, people with dementia were often prescribed antipsychotics for longer than recommended and sometimes started on higher than minimum doses. This suggests a need for better adherence to guidelines to reduce potential harms.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Smith, H. C., Petersen, I., Hayes, J., Jordan, K. P., Boman, M., Banerjee, S., et al. (2025). Antipsychotic prescriptions in people with dementia in primary care: a cohort study investigating adherence of dose and duration to UK clinical guidelines. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(25)00261-5
Vancouver
Smith HC, Petersen I, Hayes J, Jordan KP, Boman M, Banerjee S, et al. Antipsychotic prescriptions in people with dementia in primary care: a cohort study investigating adherence of dose and duration to UK clinical guidelines. The Lancet Psychiatry. 2025. doi:10.1016/s2215-0366(25)00261-5. PMID: 40967729.
BibTeX
@article{smith2025-40967729,
author = {Smith, Holly Christina and Petersen, Irene and Hayes, Joseph and Jordan, Kelvin P. and Boman, Magnus and Banerjee, Sube and Walters, Kate R and Cooper, Claudia and others},
title = {{Antipsychotic prescriptions in people with dementia in primary care: a cohort study investigating adherence of dose and duration to UK clinical guidelines}},
journal = {The Lancet Psychiatry},
year = {2025},
doi = {10.1016/s2215-0366(25)00261-5},
pmid = {40967729},
url = {https://doi.org/10.1016/s2215-0366(25)00261-5}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- In our dataset search, we identified 108 910 people with a record indicating dementia at any time.
- In total, 99 091 cases were excluded (ie, individuals with no antipsychotic prescription between the ages of 60 and 85 years between 2000 and 2023, a previous history of antipsychotics, missing deprivation information, or only one eligible prescription).
- We included 9819 people living with dementia aged 60-85 years who received their first antipsychotic prescription between 2000 and 2023 in the study. 5310 (54·1%) were female and 4509 (45·9%) were male, with a mean age of 77·1 years (SD 5·6 years), and ethnicity data were not available.
- The first treatment episode lasted a median of 7 months (IQR 6·6-8·7), exceeding NICE guidelines of 1-3 months and 18·1% [95% CI 17·4-18·9]) were initiated on a prescription above the minimum effective dose (ie, low dose).
- Of the 1781 participants who started on a moderate or high dose, 519 (29·1%) had a moderate or high dose in all quarters of the first year of treatment. 1 year after treatment initiation, 5136 (78·3%) of 6559 eligible individuals remained on medication (48·9% [95% CI 47·7-50·1] on low dose, 14·8% [13·9-15·6] on moderate or high dose of haloperidol, olanzapine, quetiapine or risperidone; and 14·6% [13·8-15·5] on other antipsychotics).
Why it matters
In UK primary care, people with dementia were often prescribed antipsychotics for longer than recommended and sometimes started on higher than minimum doses. This suggests a need for better adherence to guidelines to reduce potential harms.
New to this subject? Start with our plain-English guide: Alzheimer's in numbers →
Study details
- Study designcohort study
- Participants9,819
- Evidence strengthModerate
How this study scored 56/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Lancet Psychiatry) |
| Journal's citation record | 2 / 4 | The Lancet Psychiatry: journal h-index 216 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 9,819 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 8 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 5.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Juan Carlos Bazo‐Alvarez: h-index 19 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40967729) |
| Free to read | 2 / 2 | Free to read |
| Total | 56 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/s2215-0366(25)00261-5
- PubMed: 40967729
- Original source →
- Free full text: The Lancet Psychiatry →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in How common it is from nearby years
Also tagged “prevalence”
1,225 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,225 tagged studies.